GlassScriptPhysician profile
Michael Barry Wein
NPI 1336218650
$13,032.68
in general payments reported to CMS, 2019-2025
13 companies · $7,836 in 2025
The $7,836 reported for 2025 was more than what 87% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.88 · 2020: $1,185 · 2021: $271 · 2022: $136 · 2023: $43.33 · 2024: $3,499 · 2025: $7,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,037 · Travel and Lodging: $1,493 · Food and Beverage: $833 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,036.84 |
| Travel and Lodging | $1,492.81 |
| Food and Beverage | $833.31 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $10,864.63 | 2024-2025 | Andembry |
| Leo Pharma INC. | $1,170.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $158.83 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $150.80 | 2021-2024 | Fasenra |
| Adma Biomanufacturing LLC | $150.00 | 2024 | |
| Blueprint Medicines Corporation | $147.61 | 2024 | |
| Novartis Pharmaceuticals Corporation | $139.99 | 2025 | |
| Pfizer INC. | $113.50 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $42.45 | 2019 | |
| Glaxosmithkline, LLC. | $32.10 | 2019-2021 | |
| Genzyme Corporation | $28.06 | 2023 | |
| Alk-Abello, INC | $21.07 | 2021 | |
| Genentech USA, INC. | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.